Table 4. SVR versus mode of infection in GT2 and GT3 patients.
| Genotype 2 | Genotype 3 | ||||||||
| No SVR | SVR | p | No SVR | SVR | |||||
| N | % | N | % | N | % | N | % | ||
| Blood products | 15 | 31.3 | 33 | 68.8 | 0.629 | 35 | 37.2 | 59 | 62.8 |
| Drug use (i.v. or nasal) | 58 | 40.3 | 86 | 59.7 | 0.100 | 550 | 45.4 | 661 | 54.6 |
| Sexual transmission | 7 | 41.2 | 10 | 58.8 | 0.609 | 42 | 43.3 | 55 | 56.7 |
| Tatoos/piercing | 3 | 42.9 | 4 | 57.1 | 0.700 | 21 | 43.8 | 27 | 56.3 |
| Needle stick | 3 | 50.0 | 3 | 50.0 | 0.427 | 11 | 40.7 | 16 | 59.3 |
| Surgical/medical procedure | 9 | 39.1 | 14 | 60.9 | 0.659 | 13 | 28.3 | 33 | 71.7 |
| Medical/dental profession | 1 | 14.3 | 6 | 85.7 | 0.429 | 4 | 28.6 | 10 | 71.4 |
| Unknown | 46 | 31.1 | 102 | 68.9 | 0.227 | 187 | 39.3 | 289 | 60.7 |
(multiple answers allowed; differences between modes of infections in GT2 versus GT3 were tested for significance by Fisher's exact χ2-test without correcting for multiple testing).